此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Lung Cancer Detection by Measuring Monocyte Activity (EDLC)

2014年3月16日 更新者:Carmel Medical Center

Lung Cancer Detection and Staging by Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC)

Purpose: To evaluate the performance of Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC) analysis method in identifying lung cancer.

The study population will include a total of 950 participants, patients with lung cancer before any treatment, and healthy and COPD patients as a control group.

研究概览

地位

未知

条件

干预/治疗

详细说明

The purpose of the study is to evaluate the performance of Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC) analysis method in identifying lung cancer.

The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral Blood Mononuclear Cells (PBMC) in response to various reagents at different concentrations.

Study Design Prospective, three groups, open, comparative, controlled study. No. of Sites One Study Population Man and Women aged 18 - 90 years old. No. of Subjects A total of 950 completed, evaluated subjects will be enrolled in this study.

The groups sample size is as follows:

Group 1 - 75 subjects Group 2 - 75 subjects Group 3 - 150 subjects Group 4 - 650 subjects

Primary End Point 1. Positive and negative diagnosis (scored 0/1 dichotomously) in accordance with clinical data collected

Data Analysis and Statistics Multiple MA profiles including a huge number of MA rates values are obtained for each subject. In order to develop a dynamic clinical analysis that is updated with every new subject, and to extract patterns from this large data base, The research team designed computer programming using Data Mining tools, which combine methods from statistics and artificial intelligence with database management.

Blood test will be perform from each subject. The blood sample in eah subject will be compare to his status : healthy non smoker, healthy smoker, COPD or diagnosed with lung cancer.

研究类型

介入性

注册 (预期的)

950

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Haifa、以色列、34362
        • Carmel Medical Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 90年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria

  1. Subject signed the informed consent.
  2. Subject is between 18 to 90 years old.
  3. Lung cancer diagnosis before any treatment

Exclusion Criteria

  1. Lung cancer patients
  2. Subject has been previously treated for any type of malignant or benign tumor (for example: colon or uterus polyps removal).
  3. Subject has active infection or inflammation determined clinically at screening.
  4. Subject is currently treated with concomitant medication related directly or can affect the immune system.
  5. Subject lactating or undergoing fertility treatment.
  6. Subject has impaired judgment.
  7. Known positive HIV, hepatitis B, or hepatitis C, autoimmune disease.
  8. Known history of a significant medical disorder, which in the investigators' judgment contraindicates the patient's participation.
  9. Known hypersensitivity and/or allergy
  10. Drug or alcohol abuse (by history).
  11. Subject is participating in any other clinical trial, drug or device study within 30 days prior sample collection
  12. Relatives of the study investigators or employees of the study investigators are not allowed to participate in the study

    -

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:lung cancer diagnosis

4 arms will be included in the study:

The groups sample size is as follows:

Group 1 - Healthy non smoker- 75 subjects Group 2 - Healthy smoker- 75 subjects Group 3 - Patients diagnosed as having COPD- 150 subjects Group 4 - Patients with diagnosis of lung cancer- 650 subjects

A blood test will be taken from each patient.

a blood test will be taken from each patient

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Positive and negative diagnosis (scored 0/1 dichotomously) of lung cancer
大体时间:1 year
1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Yochai Adir, MD、Carmel Medical Center

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年4月1日

初级完成 (预期的)

2020年1月1日

研究完成 (预期的)

2021年1月1日

研究注册日期

首次提交

2014年3月10日

首先提交符合 QC 标准的

2014年3月16日

首次发布 (估计)

2014年3月18日

研究记录更新

最后更新发布 (估计)

2014年3月18日

上次提交的符合 QC 标准的更新

2014年3月16日

最后验证

2014年3月1日

更多信息

与本研究相关的术语

其他研究编号

  • CMC-13-0105-CTIL

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

Blood test的临床试验

3
订阅